thalidomide - CISMeF

Preferred Label : thalidomide;

MeSH definition : A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.;

CISMeF synonym : celgene brand of thalidomide;

MeSH hyponym : sedoval; thalomid;

MeSH CAS label : 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-;

MeSH Related Number : 50-35-1 (Thalidomide);

Registry Number MeSH : 50-35-1;

Wikipedia link : https://en.wikipedia.org/wiki/Thalidomide;

Codes EINECS : 200-031-1;

Is substance : O;

UNII : 4Z8R6ORS6L;

InChIKey : UEJJHQNACJXSKW-UHFFFAOYSA-N;

Details

Origin ID

D013792;

UMLS CUI

C0039736;

ATC code(s)
- thalidomide [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- thalidomide [Substance BNPC]
Pharmacological action(s)
- angiogenesis inhibitors [MeSH Descriptor]
- immunosuppressive agents [MeSH Descriptor]
- leprostatic agents [MeSH Descriptor]
- teratogens [MeSH Descriptor]
Record concept(s)
- sedoval [MeSH concept]
- thalidomide [MeSH concept]
- thalomid [MeSH concept]
Related MeSH Supplementary Concept(s)
- 1-O-methyl-2,3,4-tri-acetyl-6-tetrafluorophthalimido-6-deoxy-D-glucopyranose [MeSH Supplementary Concept]
- 2-(2,6-dioxopiperidin-3-yl)phthalimidine [MeSH Supplementary Concept]
- 2-(2-(3-azido-4-iodophenylpropionamido)ethoxy)thalidomide [MeSH Supplementary Concept]
- 3'-methylthalidomide [MeSH Supplementary Concept]
- 3,6'-dithiothalidomide [MeSH Supplementary Concept]
- 3-aminophthalimidoglutarimide [MeSH Supplementary Concept]
- 3-fluorothalidomide [MeSH Supplementary Concept]
- 4-fluorothalidomide [MeSH Supplementary Concept]
- 5'-hydroxythalidomide [MeSH Supplementary Concept]
- 5,N-dihydroxythalidomide [MeSH Supplementary Concept]
- 5-hydroxythalidomide [MeSH Supplementary Concept]
- ARV-825 [MeSH Supplementary Concept]
- CC 3052 [MeSH Supplementary Concept]
- CC-885 [MeSH Supplementary Concept]
- CPS 11 [MeSH Supplementary Concept]
- CPS 45 [MeSH Supplementary Concept]
- CPS 49 [MeSH Supplementary Concept]
- DT PACE regimen [MeSH Supplementary Concept]
- DT-PACE protocol [MeSH Supplementary Concept]
- EM 16 [MeSH Supplementary Concept]
- EM 240 [MeSH Supplementary Concept]
- K 2004-1c [MeSH Supplementary Concept]
- LY103 [MeSH Supplementary Concept]
- MDT protocol [MeSH Supplementary Concept]
- N-hydroxythalidomide [MeSH Supplementary Concept]
- N-phthalimidino glutaric acid [MeSH Supplementary Concept]
- N-phthalylisoglutamine [MeSH Supplementary Concept]
- SelCID-3 [MeSH Supplementary Concept]
- TCID protocol [MeSH Supplementary Concept]
- apremilast [MeSH Supplementary Concept]
- dBET1 compound [MeSH Supplementary Concept]
- hyperCDT protocol [MeSH Supplementary Concept]
- methyl 3-(4-aminophthalimido)-3-(3,4-dimethoxyphenyl)-propanoate [MeSH Supplementary Concept]
- methyl 3-(4-nitrophthalimido)-3-(3,4-dimethoxyphenyl)-propanoate [MeSH Supplementary Concept]
- phthalimidophthalimide [MeSH Supplementary Concept]
- pomalidomide [MeSH Supplementary Concept]
- supidimide [MeSH Supplementary Concept]
- taglutimide [MeSH Supplementary Concept]
- tetrafluorothalidomide [MeSH Supplementary Concept]
Semantic type(s)
- Hazardous or Poisonous Substance [UMLS semantic type]
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Product containing thalidomide (medicinal product) [SNOMED CT concept]
- Thalidomide [ICD-11 Extension code]
- Thalidomide [NCIt concept]
- Thalidomide (substance) [SNOMED CT concept]
- thalidomide [ATC Code]
- thalidomide [Substance BNPC]
- thalidomide [SNOMED Notion]
Validated automatic mappings to BTNT
- thalidomide [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients